Novartis' Fabhalta slows progression of rare kidney disease in trial

Core Viewpoint - Novartis announced that its Fabhalta drug has demonstrated a significant ability to slow the progression of a rare type of kidney disease based on the final results of a late-stage trial [1] Group 1 - The late-stage trial results indicate a meaningful impact of Fabhalta on disease progression [1]